April 29,Johnson & JohnsonPartner Addex Therapeutics announced aADX71149(JNJ-40411813) Adjunctive Administration for the Treatment ofLevetiracetamOrBrivaracetamKey Results of Phase II Study on Poorly Responsive Focal Seizures. The study did not meet its primary endpoint, as ADX71149 in combination with standard treatment showed no statistical significance in the time required for patients to reach baseline seizure frequency.
These data are from 110 evaluable patients, each of whom received 50mg or 100mg ADX71149 twice daily in addition to standard doses of levetiracetam or brivaracetam and up to three other antiepileptic drugs.Treatment. ADX71149 adjunctive medication is safe and well-tolerated.Glutamate is the primary excitatory neurotransmitter in the brain and plays a crucial role in the initiation and spread of seizures. ADX71149 is a selective positive allosteric modulator (PAM) of metabotropic glutamate receptor 2 (mGlu2), and under conditions of agonist-induced activation, positive allosteric modulation of mGlu2 receptors may help normalize excessive glutamate release during seizures.Johnson & Johnson entered into a collaboration with Addex in December 2004. Under the research collaboration and license agreement, Addex granted Johnson & Johnson an exclusive global license to develop and commercialize mGlu2 PAM compounds. Addex is eligible to receive up to €109 million in success-based development and regulatory milestone payments. Additionally, based on the net sales of the compounds, Addex is also eligible to receive low double-digit royalties.Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
